March 13, 2018 / 12:31 PM / 2 months ago

BRIEF-Abbvie Announces Positive Results From Second Phase 3 Study Of Elagolix In Women With Uterine Fibroids

March 13 (Reuters) - Abbvie Inc:

* ABBVIE ANNOUNCES POSITIVE TOPLINE RESULTS FROM SECOND PHASE 3 STUDY EVALUATING INVESTIGATIONAL ELAGOLIX IN WOMEN WITH UTERINE FIBROIDS

* ABBVIE INC - ‍SECOND OF TWO PIVOTAL PHASE 3 STUDIES (ELARIS UF-II) MET PRIMARY EFFICACY ENDPOINT AND ALL RANKED SECONDARY ENDPOINTS​

* ABBVIE INC - ‍RESULTS WERE CONSISTENT WITH FIRST PHASE 3 STUDY​

* ABBVIE INC - STUDY ALSO MET ALL RANKED SECONDARY ENDPOINTS (P<0.02) AT MONTH SIX

* ABBVIE INC - ‍RESULTS DEMONSTRATED ELAGOLIX, WITH LOW-DOSE ADD-BACK THERAPY, REDUCED HEAVY MENSTRUAL BLEEDING COMPARED TO PLACEBO​

* ABBVIE INC - ‍WOMEN IN STUDY WILL CONTINUE IN EITHER POST-TREATMENT FOLLOW-UP OR A BLINDED SIX-MONTH EXTENSION STUDY​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below